Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  3.40 3.28% 107.00 2,121,827 16:29:56
Bid Price Offer Price High Price Low Price Open Price
106.00 107.00 107.00 102.80 103.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 129.80 13.02 1.54 69.5 572
Last Trade Time Trade Type Trade Size Trade Price Currency
17:38:54 O 9 107.00 GBX

Alliance Pharma (APH) Latest News

More Alliance Pharma News
Alliance Pharma Investors    Alliance Pharma Takeover Rumours

Alliance Pharma (APH) Discussions and Chat

Alliance Pharma Forums and Chat

Date Time Title Posts
21/9/202116:16Alliance Pharma pays Dividends1,706
21/8/201817:36A Canadian Stock Worth Watching1
07/11/201615:35Alliance Pharma plc1
15/7/201310:15ALLIANCE PHARMA – 2005 Strong Riser611

Add a New Thread

Alliance Pharma (APH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Alliance Pharma trades in real-time

Alliance Pharma (APH) Top Chat Posts

Alliance Pharma Daily Update: Alliance Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 103.60p.
Alliance Pharma Plc has a 4 week average price of 101p and a 12 week average price of 97.30p.
The 1 year high share price is 110.80p while the 1 year low share price is currently 71.70p.
There are currently 534,700,305 shares in issue and the average daily traded volume is 1,572,047 shares. The market capitalisation of Alliance Pharma Plc is £572,129,326.35.
wad collector: This BB is humming with excitement ever since I acquired some in March. Usually shares drop when I buy them and the BB gets busy. I like this. Though won't buy much with the dividend. Interim results for the six months ended 30 June 2021 Strong growth from Consumer Healthcare brands and integration of Amberen complete Full year outlook in line with market expectations Alliance Pharma plc (AIM: APH), the international healthcare group, announces its interim results for the six months ended 30 June 2021 (the "Period"). HIGHLIGHTS -- The Group traded strongly in the Period with an excellent performance from Kelo-cote(TM), an uplift in revenue from Prescription Medicines and a significant contribution from recently acquired Amberen(TM) -- See-through revenue in total up 24% (+28% on a constant currency basis ("CCY")) to GBP80.9m; like-for-like ("LFL") see-through revenue, which excludes Amberen, up 9% (+12% CCY); statutory revenue up 27% to GBP78.6m (H1 2020 GBP61.7m) o Strong performance from Consumer Healthcare brands, with see-through revenue up 30% overall (+35% CCY) -- Kelo-cote revenue up 54% (+62% CCY) -- LFL Consumer Healthcare revenue up 8% (+12% CCY) o Prescription Medicines revenue up 12% (+12% CCY) -- Underlying gross margin up 4.7 % to 63.8% of see-through revenue (H1 2020: 59.1%), reflecting favourable changes in product mix; statutory gross margin up 3.1% to 65.6% (H1 2020: 62.5%) -- Underlying profit before tax up 24% to GBP20.1m (H1 2020: GBP16.3m); reported profit before tax GBP16.5m (H1 2020: GBP0.6m) -- Free cash flow GBP6.5m (H1 2020: GBP10.5m), reflecting the expected reversal of favourable working capital movements in Q4 2020 and the timing of sales within the Period -- Leverage reduced to 2.21 times from 2.43 times at December 2020 and expected to fall below 2.0 times by the end of the year -- Amberen integration complete and trading in line with management expectations -- Interim dividend payment of 0.563p, up 5% (interim dividend 2020: 0.536p)
2vdm: The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://www.alliancepharmaceuticals.com/investors/
2vdm: RNSthis a.m.: Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021. A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at alliancepharma@buchanan.uk.com. A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link: hxxps://webcasting.buchanan.uk.com/broadcast/60180f8da6bfbf43d06ac2ea The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://www.alliancepharmaceuticals.com/investors/. For more information, please contact Buchanan on 020 7466 5000 or email alliancepharma@buchanan.uk.com.
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days ago and part of our discussion includes APH and some others with a similar business model. We also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 39) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !! Happy New Lockdown !! WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheeliedealer-39-2064-profit-aph-clin-merc-pdd-axs-som-itm-adm-swg-vle-ai
winnings1: Has anyone here had a look at Beximco Pharmaceuticals (BXP) This company has been appointed to be the sole distributor of the Oxford vaccine for the whole of Bangladesh. The share price has risen significantly off late, but more to come IMHO. Cheers. But as always do your own research. ws
wba1: Interesting acquisition. I have held this share for a few years, having bought in the low 40s. I originally bought as the business model bears some resemblance (although more OTC focused) to Galen, a company which made me very good profits in the early 2000s. And the more I see of APH the more it behaves like Galen - low risk, throws off free cash flow reliably and makes few mistakes in its dealings. I suspect this deal will be the last until 2022 and I may look to slice some profit if it tops 100p.
amunro: Tesla is an interesting one. Are they are a car maker or innovator of next gen technology like self driving cars and batteries? As an investor sometimes you just need to follow the market, make money, with the view to getting out when things dive. Its all about managing risk. I got out of APH as I want the money to grow faster than APH offers.
winnings1: I consider APH a sound and quite safe stock in the turbulent markets - of which we have seen some signs yesterday, and almost certainly more turbulance to come, IMHO. In fact, also in the unit trusts terratory, I am mainly invested in the health sector (e.g. Schroder Global Healthcare unit trust). I would, for example, not touch a madly overvalued stock like Tesla, where there is a chance of an implosion some day. We are living in weird times, some shere prices rising out of the pan, yet no certainty anywhere. Take care, keep healthy. Cheeers, WS
winnings1: If an up-to-date purchase (i.e. today) the price would be up, a sale then down, But it could be a correction entry from a deal a few days ago, in which case it explains the then fall in the share price.
winnings1: Share price currently just around 70p, that is cheap in my view. Chairman and his wife bought in June at 77.7p, and at that price the shares were inexpensive, they now look distinctly cheap. I topped up and may yet do some more. Medicines will not go out of fashion.
Alliance Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Alliance P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 16:57:03